A citation-based method for searching scientific literature

Ralph G Zinner, Bonnie S Glisson, Frank V Fossella, Katherine M W Pisters, Merril S Kies, Pamela M Lee, Erminia Massarelli, Bradley Sabloff, Herbert A Fritsche, Jae Y Ro, Nelson G Ordonez, Hai T Tran, Ying Yang, Terry L Smith, Robert D Mass, Roy S Herbst. Lung Cancer 2004
Times Cited: 80







List of co-cited articles
890 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
U Gatzemeier, G Groth, C Butts, N Van Zandwijk, F Shepherd, A Ardizzoni, C Barton, P Ghahramani, V Hirsh. Ann Oncol 2004
250
71


Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
35

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
32

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
32

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
Gerald Clamon, James Herndon, Jeffrey Kern, Ramaswamy Govindan, Jennifer Garst, Dorothy Watson, Mark Green. Cancer 2005
80
32

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
F R Hirsch, M Varella-Garcia, W A Franklin, R Veve, L Chen, B Helfrich, C Zeng, A Baron, P A Bunn. Br J Cancer 2002
162
30

Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'Meara, Raffaella Smith, Adrian Parker,[...]. Nature 2004
572
27

Erlotinib in previously treated non-small-cell lung cancer.
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins,[...]. N Engl J Med 2005
26

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Hisayuki Shigematsu, Takao Takahashi, Masaharu Nomura, Kuntal Majmudar, Makoto Suzuki, Huei Lee, Ignacio I Wistuba, Kwun M Fong, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. Cancer Res 2005
489
26

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Federico Cappuzzo, Marileila Varella-Garcia, Hisayuki Shigematsu, Irene Domenichini, Stefania Bartolini, Giovanni L Ceresoli, Elisa Rossi, Vienna Ludovini, Vanesa Gregorc, Luca Toschi,[...]. J Clin Oncol 2005
295
25

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Julien Mazières, Solange Peters, Benoit Lepage, Alexis B Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Hélène Blons, Audrey Mansuet-Lupo, Thierry Urban,[...]. J Clin Oncol 2013
376
25

HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Petra Heinmöller, Christof Gross, Kurt Beyser, Claudia Schmidtgen, Gerd Maass, Michele Pedrocchi, Josef Rüschoff. Clin Cancer Res 2003
104
21

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Primo N Lara, Luko Laptalo, Jeff Longmate, Derick H M Lau, Regina Gandour-Edwards, Paul H Gumerlock, James H Doroshow, David R Gandara. Clin Lung Cancer 2004
61
27

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin,[...]. J Clin Oncol 2003
20

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Maria E Arcila, Jamie E Chaft, Khedoudja Nafa, Sinchita Roy-Chowdhuri, Christopher Lau, Michael Zaidinski, Paul K Paik, Maureen F Zakowski, Mark G Kris, Marc Ladanyi. Clin Cancer Res 2012
258
20

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Roy S Herbst, Giuseppe Giaccone, Joan H Schiller, Ronald B Natale, Vincent Miller, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Ira Oliff, James A Reeves,[...]. J Clin Oncol 2004
18

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giuseppe Giaccone, Roy S Herbst, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Vincent Miller, Ronald B Natale, Joan H Schiller, Joachim Von Pawel, Anna Pluzanska,[...]. J Clin Oncol 2004
18

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Lee M Krug, Vincent A Miller, Jyoti Patel, John Crapanzano, Christopher G Azzoli, Jorge Gomez, Mark G Kris, Robert T Heelan, Barbara Pizzo, Leslie Tyson,[...]. Cancer 2005
42
35

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
J De Grève, E Teugels, C Geers, L Decoster, D Galdermans, J De Mey, H Everaert, I Umelo, P In't Veld, D Schallier. Lung Cancer 2012
194
18

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Mark G Kris, Ronald B Natale, Roy S Herbst, Thomas J Lynch, Diane Prager, Chandra P Belani, Joan H Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler,[...]. JAMA 2003
17

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Federico Cappuzzo, Fred R Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini,[...]. J Natl Cancer Inst 2005
17

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
16

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
William Pao, Vincent Miller, Maureen Zakowski, Jennifer Doherty, Katerina Politi, Inderpal Sarkaria, Bhuvanesh Singh, Robert Heelan, Valerie Rusch, Lucinda Fulton,[...]. Proc Natl Acad Sci U S A 2004
16

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H Schiller, David Harrington, Chandra P Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H Johnson. N Engl J Med 2002
16

Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand,[...]. N Engl J Med 2005
16

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Federico Cappuzzo, Lynne Bemis, Marileila Varella-Garcia. N Engl J Med 2006
167
16

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
16

HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
Caterina Pellegrini, Monica Falleni, Antonio Marchetti, Barbara Cassani, Monica Miozzo, Fiamma Buttitta, Massimo Roncalli, Guido Coggi, Silvano Bosari. Clin Cancer Res 2003
76
15

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
15

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
15

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
955
15

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
Dongfeng Tan, George Deeb, Jianmin Wang, Harry K Slocum, Janet Winston, Sam Wiseman, Amy Beck, Sheila Sait, Timothy Anderson, Chukwumere Nwogu,[...]. Diagn Mol Pathol 2003
55
20


Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
J Brabender, K D Danenberg, R Metzger, P M Schneider, J Park, D Salonga, A H Hölscher, P V Danenberg. Clin Cancer Res 2001
402
13

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Román Pérez-Soler, Abraham Chachoua, Lisa A Hammond, Eric K Rowinsky, Mark Huberman, Daniel Karp, James Rigas, Gary M Clark, Pedro Santabárbara, Philip Bonomi. J Clin Oncol 2004
862
13

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore, Jacques Gaudreault, Lisa A Damico,[...]. J Clin Oncol 2004
13

Untangling the ErbB signalling network.
Y Yarden, M X Sliwkowski. Nat Rev Mol Cell Biol 2001
13

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Roy S Herbst, David H Johnson, Eric Mininberg, David P Carbone, Ted Henderson, Edward S Kim, George Blumenschein, Jack J Lee, Diane D Liu, Mylene T Truong,[...]. J Clin Oncol 2005
432
13

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Roy S Herbst, Angela M Davies, Ronald B Natale, Thao P Dang, Joan H Schiller, Linda L Garland, Vincent A Miller, David Mendelson, Annick D Van den Abbeele, Yulia Melenevsky,[...]. Clin Cancer Res 2007
65
16

The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
Lingxiang Liu, Xiaoyan Shao, Wen Gao, Jianling Bai, Rongsheng Wang, Puwen Huang, Yongmei Yin, Ping Liu, Yongqian Shu. J Thorac Oncol 2010
80
13

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
13

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Hisayuki Shigematsu, Li Lin, Takao Takahashi, Masaharu Nomura, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong, Huei Lee, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. J Natl Cancer Inst 2005
12

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
12

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman,[...]. N Engl J Med 2006
12

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y Wu, Seungchan Yang, Graham Carpenter, Adi F Gazdar, Senthil K Muthuswamy, Carlos L Arteaga. Cancer Cell 2006
332
12

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
331
12

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Leena Gandhi, Rastislav Bahleda, Sara M Tolaney, Eunice L Kwak, James M Cleary, Shuchi S Pandya, Antoine Hollebecque, Richat Abbas, Revathi Ananthakrishnan, Anna Berkenblit,[...]. J Clin Oncol 2014
136
12

HER2/neu expression in malignant lung tumors.
Fred R Hirsch, Wilbur A Franklin, Robert Veve, Marileila Varella-Garcia, Paul A Bunn. Semin Oncol 2002
83
11

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Roy S Herbst, Diane Prager, Robert Hermann, Lou Fehrenbacher, Bruce E Johnson, Alan Sandler, Mark G Kris, Hai T Tran, Pam Klein, Xin Li,[...]. J Clin Oncol 2005
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.